^
    Back
    Association details:
    Biomarker:MET mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:glesatinib (MGCD265) (VEGFR inhibitor, c-MET inhibitor, AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

    Excerpt:
    ......
    Trial ID:
    NCT02544633
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

    Excerpt:
    ......
    Trial ID:
    NCT00697632
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Target Oncol
    Title:

    Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors

    Published date:
    12/02/2022
    Excerpt:
    Antitumor activity was observed with glesatinib FBS 1050 mg twice daily and SDD 750 mg twice daily in tumors harboring MET/AXL alteration or aberrant protein expression, particularly in patients with non--small cell lung cancer (NSCLC). In patients with NSCLC, the objective response rate was 25.9% in those with MET/AXL mutation or amplification and 30.0% in a subset with MET-activating mutations. All six partial responses occurred in patients with tumors carrying MET exon 14 deletion mutations.
    DOI:
    10.1007/s11523-022-00931-9
    Trial ID:
    NCT00697632